BioXcel Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
BioXcel Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2019 to Q3 2024.
  • BioXcel Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $461K, a 39.5% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $461K -$301K -39.5% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $538K -$296K -35.5% Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $613K -$293K -32.3% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $688K -$288K -29.5% Dec 31, 2023 10-Q 2024-11-14
Q3 2023 $762K -$283K -27.1% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $834K -$280K -25.1% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $906K -$275K -23.3% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $976K -$271K -21.7% Dec 31, 2022 10-K 2024-03-22
Q3 2022 $1.05M -$267K -20.4% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $1.11M -$263K -19.1% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $1.18M -$259K -18% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $1.25M -$264K -17.5% Dec 31, 2021 10-K 2023-03-16
Q3 2021 $1.31M -$274K -17.3% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $1.38M +$276K +25.1% Jun 30, 2021 10-Q 2021-08-10
Q1 2021 $1.44M +$287K +24.9% Mar 31, 2021 10-Q 2021-05-10
Q4 2020 $1.51M +$318K +26.7% Dec 31, 2020 10-K 2022-03-11
Q3 2020 $1.59M +$387K +32.3% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $1.1M -$145K -11.6% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $1.15M -$140K -10.8% Mar 31, 2020 10-Q 2020-05-12
Q4 2019 $1.19M Dec 31, 2019 10-K 2021-03-12
Q3 2019 $1.2M Sep 30, 2019 10-Q 2019-11-14
Q2 2019 $1.25M Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $1.29M Mar 31, 2019 10-Q 2019-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.